4. Methodology
4.2. Transformation Method Experimentation
4.2.1. Data Set Generation
The recommendations based on this study are as follows:
102
1. The high prevalence of renal dysfunction and electrolyte disorders in patients with liver cirrhosis from this study, and the association with the severity of the underlying liver disease makes it important to screen for renal dysfunction and acid-base disorders in these patients.
2. It is important to involve the nephrologists once renal dysfunction is identified.
3. A meticulous clinical history, physical examination, abdominal ultrasound and assessment of urine and serum electrolytes can help in establishing the presence and possible aetiology of renal dysfunction in patients with liver cirrhosis.
4. The risk factors for renal dysfunction i.e. dehydration, hyponatraemia, acidosis and encephalopathy in liver cirrhotics should be prevented and addressed vigorously as much as possible in order to avoid rapid worsening of underlying liver disease.
5. The laboratory markers of renal function, i.e. serum creatinine, sodium and other electrolytes; and urinary sodium and specific gravity should routinely be assessed during the evaluation of all cirrhotic patients, especially those with ascites, and monitored during the management of these patients. This reduces the likelihood of early or further hepatic decompensation and thereby reducing mortality and morbidity.
6. Most of the risk factors for liver cirrhosis in this study, are preventable, thus, being proactive and avoiding them will go a long way to reduce the incidence and prevalence of liver cirrhosis. E.g. health education addressing all age groups, vaccination against HBV in populations at risk, proposing health policies aimed at reducing alcohol consumption and promoting safe injection practices in our healthcare facilities etc.
REFERENCES
1. Pradhan S. Redefining Cirrhosis – a brief review. J Pathol Nepal. 2013; 3(6).
103
2. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006; 74(5):756-62.
3. Bacon BR. Cirrhosis and its complications. 2011. In: Harrison’s Principles of Internal Medicine [Internet]. McGraw- Hill Companies. 18th.
4. Sivanathan V, Kittner JM, Sprinzl MF, Weinmann A, Koch S, Wiltink J, et al. [Etiology and complications of liver cirrhosis: data from a German centre]. Dtsch Med
Wochenschr. 2014; 139(36):1758-62.
5. Goossens N, Nakagawa S, Hoshida Y. Molecular prognostic prediction in liver cirrhosis.
World J Gastroenterol. 2015; 21(36):10262-73.
6. Lesi OA, Kehinde MO, Anomneze EE. Chronic liver disease in Lagos: a clinicopathological study. Niger Postgrad Med J. 2004 11(2):91-6.
7. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013;
310(6):591-606.
8. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;
58(3):593-608.
9. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014; 12:145.
104
10. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis:
incidence and risk factors. Gastroenterol. 2004; 127(5): S35-50
11. Rockey DC, Friedman SL. In Zakim and Boyer's hepatology: a textbook of liver disease.
Hepatic fibrosis and cirrhosis. Elsevier; 2012. 6th Edition, Philadelphia
12. Sola E, Gines P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol. 2010; 53(6):1135-45.
13. Runyon BA. A primer on detecting cirrhosis and caring for these patients without causing harm. Int J Hepatol. 2011; 2011.
14. Prakash J, Mahapatra AK, Ghosh B, Arora P, Jain AK. Clinical spectrum of renal disorders in patients with cirrhosis of liver. Ren Fail. 2011; 33(1):40-6.
15. Otegbayo JA. A review of hepatorenal syndrome. Niger J Gastroenterol Hepatol 2010; 2 (2):67-72.
16. Qureshi MO, Shafqat F, Dar FS, Salih M, Khokhar N. Renal failure in patients with end stage liver disease and its impact on clinical outcome. J Coll Physicians Surg Pak 2014;
24:628-31.
17. Attia KA, N'Dri Yoman AT, Mahassadi AK, Ackoundou-N'guessan K C, Kissi HY, Bathaix YF. Impact of renal failure on survival of African patients with cirrhosis. Saudi J Kidney Dis Transpl. 2008; 19(4):587-92.
18. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015; 62(4):968-74.
105
19. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008; 48 Suppl 1: S93-103.
20. Gentilini P, Laffi G, La Villa G, Romanelli RG, Blendis LM. Ascites and hepatorenal syndrome during cirrhosis: two entities or the continuation of the same complication? J Hepatol. 1999; 31(6):1088-97.
21. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;
62(1):131-7.
22. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;
48(6):2064-77.
23. Badalamenti S, Graziani G, Salerno F, Ponticelli C. Hepatorenal syndrome: new perspectives in pathogenesis and treatment. Archives of internal medicine. 1993;
153(17):1957-67.
24. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009; 361(13):1279-90.
25. Yeung E, Yong E, Wong F. Renal dysfunction in cirrhosis: diagnosis, treatment and prevention. MedGenMed. 2004; 6(4):9.
26. Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care.
2010; 14(2):214.
27. Choi YJ, Kim JH, Koo JK, Lee CI, Lee JY, Yang JH, et al. Prevalence of renal
dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal.
Clin Mol Hepatol. 2014; 20(2):185-91.
106
28. Iovanescu VF, Streba CT, Ionescu M, Constantinescu AF, Vere CC, Rogoveanu I, et al.
Diabetes mellitus and renal involvement in chronic viral liver disease. J Med Life. 2015;
8(4):483-7.
29. Marin Serrano E, Segura-Cabral JM. Usefulness of ultrasonography for the diagnosis of diffuse liver disease.Rev Esp Enferm Dig. 2011;103(5):227-31.
30. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001; 344(7):495-500.
31. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371(9615):838-51.
32. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003; 37(2):233-43.
33. Madan K, Mehta A. Management of renal failure and ascites in patients with cirrhosis.
Int J Hepatol.2011; 2011.
34. Ginès P, Fernández J, Durand F, Saliba F. Management of critically-ill cirrhotic patients.
J Hepatol. 2012; 56: S13-24.
35. Muciño-Bermejo J, Carrillo-Esper R, Uribe M, Méndez-Sánchez N. Acute kidney injury in critically ill cirrhotic patients: a review. Ann Hepatol. 2012; 11:301-10.
36. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, Uriz J, Quinto L, Ventura PJ, et al.
A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001;
34(1):46-52.
107
37. Martin-Llahi M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, et al.
Prognostic importance of the cause of renal failure in patients with cirrhosis.
Gastroenterology. 2011; 140(2):488-96.
38. World Health Organization. International statistical classification of diseases and related health problems. World Health Organization; 2004.
39. Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J Hepatol. 2008; 49(5):732-8.
40. Ndububa DA, Ojo OS, Adetiloye VA, Aladegbaiye AO, Adebayo RA, Adekanle O. The contribution of alcohol to chronic liver disease in patients from South-west Nigeria.
Niger J Clin Pract 2010; 13(4):360-4.
41. Adeniji KA, Anjorin AS. Histopathological assessment of the pattern of liver cirrhosis in a tropical population. Afr J Med Med Sci. 2002; 31(4):367-9.
42. Nwokediuko SC, Osuala PC, Uduma UV, Alaneme AK, Onwuka CC, Mesigo C. Pattern of liver disease admissions in a Nigerian tertiary hospital. Niger J Clin Pract 2013;
16(3):339-42.
43. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55.
44. Wait S, Chen DS. Towards the eradication of hepatitis B in Taiwan. Kaohsiung J Med Sci. 2012; 28(1):1-9.
108
45. Musa BM, Bussell S, Borodo MM, Samaila AA, Femi OL. Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: a systematic review and meta-analysis. Niger J Clin Pract. 2015; 18(2):163-72.
46. Attia KA, Eholie S, Messou E, Danel C, Polneau S, Chenal H, et al. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients.
World J Hepatol. 2012; 4(7):218-23.
47. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3(2):47-52.
48. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.
49. Scorza M, Elce A, Zarrilli F, Liguori R, Amato F, Castaldo G. Genetic diseases that predispose to early liver cirrhosis. Int J Hepatol. 2014; 2014.
50. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. The Am J Gastroenterol. 2004; 99(8):1510-6.
51. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis.
Hepatology. 2010; 51(4):1445-9.
109
52. Huo TI, Lee SD, Lin HC. Selecting an optimal prognostic system for liver cirrhosis: the model for end‐stage liver disease and beyond. Liver Int. 2008; 28(5):606-13.
53. Muir AJ. Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care. Top Antivir Med. 2014;22(4):685-9.
54. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology.
1998;27(1):264-72.
55. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: A European study. Gut. 2003;52(1):134-9.
56. Ben-Haim M, Carmiel M, Katz P, Shabtai E, Oren R, Nakache R. Is the model of end-stage liver disease (MELD) valid in Israel? A critical analysis of liver transplant waiting list mortality. IMAJ. 2006;8(9):605-9.
57. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology.
2003;124(1):91-6.
58. Skelly MM, James PD, Ryder SD. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol. 2001;35(2):195-9.
59. Qamar AA, Grace ND. Abnormal haematological indices in cirrhosis. Can J Gastroenterol 2009;23(6):441.
60. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J.
2003;84(932):307-12.
110
61. El-Bokl MA, Senousy BE, El-Karmouty KZ, Mohammed Iel K, Mohammed SM, Shabana SS, et al. Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites. World J Gastroenterol. 2009;15(29):3631-5.
62. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3):726-36.
63. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T.
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357(9262):1069-75.
64. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93(1):44-8.
65. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC gastroenterology. 2011; 11:91.
66. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest. 2004;114(1):5-14.
67. Betrosian AP, Agarwal B, Douzinas EE. Acute renal dysfunction in liver diseases. World J Gastroenterol. 2007;13(42):5552-9.
68. Graupera I, Cardenas A. Diagnostic Approach to Renal Failure in Cirrhosis. Clinical Liver Disease. 2013;2(3).
69. Adebayo D, Morabito V, Davenport A, Jalan R. Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int. 2015;87(3):509-15.
111
70. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122(4):923-30.
71. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease:
Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-100.
72. Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults: Part I. Definition, disease stages, evaluation, treatment, and risk factors. Am Fam Physician. 2004;70(5):869-76.
73. Kidney disease outcomes quality initiative: Clinical practice guidelines for chronic kidney disease. Evaluation, classification and stratification. Am J Kidney diseases 2002;
39:1-66.
74. Bittencourt PL, Farias AQ, Terra C. Renal failure in cirrhosis: Emerging concepts. World J Hepatol. 2015;7(21):2336-43.
75. Wu CC, Yeung LK, Tsai WS, Tseng CF, Chu P, Huang TY, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol.
2006;65(1):28-33.
76. Cardenas A, Arroyo V. Renal and circulatory dysfunction in liver cirrhosis. Pathogenesis and treatment. Ann Gastroenterol. 2007;14(3).
77. Chaimovitz C, Szylman P, Alroy G, Better OS. Mechanism of increased renal tubular sodium reabsorption in cirrhosis. Am J Med 1972; 52:198-202.
112
78. Angeli P, Gatta A, Caregaro L, Menon F, Sacerdoti D, Merkel C et al. Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest. 1990; 20:111-7.
79. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010; 53:397-417
80. Bernardi M, Santi L. Renal sodium retention in pre-ascitic cirrhosis: The more we know about the puzzle, the more it becomes intricate. J Hepatol. 2010; 53:790–2.
81. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004; 350:1646–54.
82. Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol.
2011;17(10):1237-48.
83. Bernardi M, Ricci CS, Santi L. Hyponatremia in Patients with Cirrhosis of the Liver. J Clin Med. 2014;4(1):85-101.
84. Cholongitas E, Goulis J, Arsos G, Birtsou C, Nakouti T, Papadopoulou S. Association between ratio of sodium to potassium in random urine samples and renal dysfunction and mortality in patients with decompensated cirrhosis. Clin Gastroenterol Hepatol. 2013;
11(7):862-7.
85. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis:
pathophysiological basis of therapy and current management. J Hepatol. 2003;38 S 1:
S69-89.
86. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342(21):1581-9.
113
87. Angeli P, Wong F, Watson H, Gines P, CAPPS Investigators. Hyponatremia in cirrhosis:
results of a patient population survey. Hepatol. 2006; 44:1535–1542.
88. Barakat AA, Metwaly AA, Nasr FM, El-Ghannam M, El-Talkawy MD, Taleb HA.
Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis. Electron physician. 2015;7(6):1349-58.
89. Shaikh S, Mal G, Khalid S, Baloch GH, Akbar Y. Frequency of hyponatraemia and its influence on liver cirrhosis-related complications. J Pak Med Assoc. 2010;60(2):116-20.
90. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.
Hepatology 1996; 23:164–76.
91. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of Hepatorenal syndrome in cirrhosis. Gut. 2007; 56:1310–8.
92. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A et al. Diagnosis,
treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55(6):1241-8.
93. Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol. 2009;15(24):2960-74.
94. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52(4):605-13.
95. Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. Int J Hepatol. 2012;2012.
114
96. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites.
Gastroenterol. 1993;105(1):229-36.
97. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liv Int. 2006;26(7):834-9.
98. Shahid A, Qureshi H, Nizami F, Zuberi SJ. Electrolytes in liver disease--a preliminary study. J Pak Med Assoc. 1983;33(12):289-93.
99. DuBose Thomas D. Acidosis and Alkalosis. 2015. In: Harrison's Principles of internal Medicine [Internet]. Mc Graw- Hill Education; [3985].
100. Hassan H, Joh JH, Bacon BR, Bastani B. Evaluation of serum anion gap in patients with liver cirrhosis of diverse etiologies. Mt Sinai J Med. 2004;71(4):281-4.
101. Ahya S N, Jose Soler M, Levitsky J, Batlle D. Acid- base and potassium disorders in liver disease. Semin Nephrol. 2006;26(6):466-70.
102. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver international : official journal of the International Association for the Study of the Liver. 2006;26(7):834-9.
103. Carvalho GC, Regis Cde A, Kalil JR, Cerqueira LA, Barbosa DS, Motta MP et al. Causes of renal failure in patients with decompensated cirrhosis and its impact in hospital mortality. Ann Hepatol. 2012;11(1):90-5.
115
104. Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol.
2012;56(4):810-8.
105. Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, et al. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A
Prospective Cohort Study. Intel J Nephrol. 2015;2015.
106. Arogundade FA, Awowole IO, Esan O, Sanusi AA, Akinsola A. Hepatorenal Syndrome In Nigeria: A Review of Pathophysiology, Clinical Features and Management.
IFEMEDJOURNAL GUT 2008;14(1):29-34.
107. Kim JH, Lee JS, Lee SH, Bae WK, Kim NH, Kim KA, et al. The association between the serum sodium level and the severity of complications in liver cirrhosis. Korean J Intern Med. 2009;24(2):106-12.
108. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol. 2002;97(8):2046-50.
109. Luyckx VA, Steenkamp V, Stewart MJ. Acute renal failure associated with the use of traditional folk remedies in South Africa. Ren Fail. 2005;27(1):35-43.
110. Dugo M, Gatto R, Zagatti R, Gatti P, Cascone C. [Herbal remedies: nephrotoxicity and drug interactions]. G Ital Nefrol. 2009;27: S5-9.
111. Rahman M, Shad F, Smith MC. Acute kidney injury: a guide to diagnosis and management. Am Fam Physician. 2012;86(7):631-9.
116
112 Steiner RW. Interpreting the fractional excretion of sodium. Am J Med. 1984;77(4):699-702.
113. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 2002;62(6):2223-9.
114. Schrier RW. Diagnostic value of urinary sodium, chloride, urea, and flow. Am Soc Nephrol. 2011;22(9):1610-3.
115. Alexander Kratz, Michael A. Pesce, Robert C. Basner, Andrew J. Einstein. Laboratory Values of Clinical Importance. 2015 11/3/2016. In: Harrison's Principles of Internal Medicine [Internet]. McGraw-Hill Education. 19th [3985].
116. Fang JT, Tsai MH, Tian YC, Jenq CC, Lin CY, Chen YC et al. Outcome predictors and new score of critically ill cirrhotic patients with acute renal failure. Nephrol Dial Transplant. 2008;23:1961–9.
117. Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting (TIPS) for the prevention of variceal re-bleeding.
Digestion.2003;67(3):146-53.
118. Kakazu E, Kondo Y, Shimosegawa T. The relationship between renal dysfunction and abnormalities of the immune system in patients with decompensated cirrhosis. ISRN Gastroenterol. 2012;2012.
117
119. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology.
2001;33(2):464-70.
120. Fagundes C, Barreto R, Guevara M, Garcia E, Sola E, Rodriguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. Journal of hepatology. 2013 Sep;59(3):474-81.
121. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci. 2006;1(1):9-14.
122. Blei AT, Córdoba J, Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J. Gastroenterol. 2001;96(7):1968-76.
123. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD.
J Hepatol. 2005; 42(1):S100-7
124. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group.
Gut. 1997;41(6):845-50.
125. Miles BE, Paton A, De Wardener HE. Maximum urine concentration. Br Med J 1954;2(4893):901- 5.
126. Bain BJ. Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol. 1996;49(8):664-6.
127. George TI. Malignant or benign leucocytosis. Hematology Am Soc Hematol Educ Program. 2012;2012(1):475-84.
118
128. ILO. International Standard Classification of Occupations (ISCO-08). International Labour Office. 2012;1 14.
129. Beutler E, West C. Hematologic differences between African-Americans and whites: the roles of iron deficiency and alpha-thalassemia on hemoglobin levels and mean
corpuscular volume. Blood. 2005;106(2):740-5.
130. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy.
Hepatology. 2009;49(3):1017-44
119 APPENDIX I